Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."
Judge Margaret Seymour held a hearing to better understand the facts of the case before deciding whether it should go forward.
Natera alleges that Bio-Reference broke a contract by promoting a NIPS test based on Illumina technology over Panorama.
The university claims that Genia's patents are based on technology that was developed by UCSC researchers and that UCSC should have ownership of them.
The lawsuit, filed last week against Illumina, CEO Francis deSouza, and CFO Marc Stapley, claims that defendants made materially false and misleading statements between July 26 and Oct. 10.
Alere said its would-be acquirer has no grounds for seeking termination, but Abbott cited adverse material events as a basis for ending the deal.
The case is being framed as either upholding a strong patent regime or dealing a blow to US-based manufacturing as part of the global supply chain.
The GenomeWeb Index, which fell nearly 9 percent in October, rebounded to a 1 percent gain in November, but still underperformed the Dow and Nasdaq.
Investors in Theranos may lose out and some are filing lawsuits, the Wall Street Journal reports.
In its lawsuit papers, Walgreens says Theranos voided more than 11 percent of test reports sent to Walgreens customers, according to the Wall Street Journal.
The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.
The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.
The first Reproducibility Project: Cancer Biology papers show mixed results.
In Nature this week: mobile phone-based targeted DNA sequencing, and more.